Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project.


Journal

Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902

Informations de publication

Date de publication:
14 Jun 2019
Historique:
received: 05 04 2019
accepted: 28 05 2019
entrez: 16 6 2019
pubmed: 16 6 2019
medline: 20 12 2019
Statut: epublish

Résumé

The objective of this study was to assess the cumulative incidence of invasive candidiasis (IC) in intensive care units (ICUs) in Europe. A multinational, multicenter, retrospective study was conducted in 23 ICUs in 9 European countries, representing the first phase of the candidemia/intra-abdominal candidiasis in European ICU project (EUCANDICU). During the study period, 570 episodes of ICU-acquired IC were observed, with a cumulative incidence of 7.07 episodes per 1000 ICU admissions, with important between-center variability. Separated, non-mutually exclusive cumulative incidences of candidemia and IAC were 5.52 and 1.84 episodes per 1000 ICU admissions, respectively. Crude 30-day mortality was 42%. Age (odds ratio [OR] 1.04 per year, 95% CI 1.02-1.06, p < 0.001), severe hepatic failure (OR 3.25, 95% 1.31-8.08, p 0.011), SOFA score at the onset of IC (OR 1.11 per point, 95% CI 1.04-1.17, p 0.001), and septic shock (OR 2.12, 95% CI 1.24-3.63, p 0.006) were associated with increased 30-day mortality in a secondary, exploratory analysis. The cumulative incidence of IC in 23 European ICUs was 7.07 episodes per 1000 ICU admissions. Future in-depth analyses will allow explaining part of the observed between-center variability, with the ultimate aim of helping to improve local infection control and antifungal stewardship projects and interventions.

Sections du résumé

BACKGROUND BACKGROUND
The objective of this study was to assess the cumulative incidence of invasive candidiasis (IC) in intensive care units (ICUs) in Europe.
METHODS METHODS
A multinational, multicenter, retrospective study was conducted in 23 ICUs in 9 European countries, representing the first phase of the candidemia/intra-abdominal candidiasis in European ICU project (EUCANDICU).
RESULTS RESULTS
During the study period, 570 episodes of ICU-acquired IC were observed, with a cumulative incidence of 7.07 episodes per 1000 ICU admissions, with important between-center variability. Separated, non-mutually exclusive cumulative incidences of candidemia and IAC were 5.52 and 1.84 episodes per 1000 ICU admissions, respectively. Crude 30-day mortality was 42%. Age (odds ratio [OR] 1.04 per year, 95% CI 1.02-1.06, p < 0.001), severe hepatic failure (OR 3.25, 95% 1.31-8.08, p 0.011), SOFA score at the onset of IC (OR 1.11 per point, 95% CI 1.04-1.17, p 0.001), and septic shock (OR 2.12, 95% CI 1.24-3.63, p 0.006) were associated with increased 30-day mortality in a secondary, exploratory analysis.
CONCLUSIONS CONCLUSIONS
The cumulative incidence of IC in 23 European ICUs was 7.07 episodes per 1000 ICU admissions. Future in-depth analyses will allow explaining part of the observed between-center variability, with the ultimate aim of helping to improve local infection control and antifungal stewardship projects and interventions.

Identifiants

pubmed: 31200780
doi: 10.1186/s13054-019-2497-3
pii: 10.1186/s13054-019-2497-3
pmc: PMC6567430
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

219

Références

Intensive Care Med. 2009 Jan;35(1):55-62
pubmed: 18972101
Int J Antimicrob Agents. 2008 Nov;32 Suppl 2:S87-91
pubmed: 19013346
JAMA. 2009 Dec 2;302(21):2323-9
pubmed: 19952319
Crit Care Med. 2011 Apr;39(4):665-70
pubmed: 21169817
Mycoses. 2012 Jan;55(1):73-9
pubmed: 21668521
Intensive Care Med. 2013 Dec;39(12):2092-106
pubmed: 24105327
Intensive Care Med. 2014 Jun;40(6):839-45
pubmed: 24807083
Intensive Care Med. 2015 Sep;41(9):1601-10
pubmed: 26077063
Ann Intensive Care. 2016 Dec;6(1):2
pubmed: 26743881
Crit Care. 2016 Mar 09;20:53
pubmed: 26956367
Intensive Care Med. 2017 Apr;43(4):509-518
pubmed: 28271321
J Infect. 2017 Jul;75(1):59-67
pubmed: 28366686

Auteurs

Matteo Bassetti (M)

Infectious Diseases Clinic, Department of Medicine University of Udine and Santa Maria Misericordia Hospital, Piazzale Santa Maria della Misericordia 15, 33100, Udine, Italy. matteo.bassetti@asuiud.sanita.fvg.it.
Department of Health Sciences, University of Genoa, Genoa, Italy. matteo.bassetti@asuiud.sanita.fvg.it.

Daniele R Giacobbe (DR)

Department of Health Sciences, University of Genoa, Genoa, Italy.

Antonio Vena (A)

Infectious Diseases Clinic, Department of Medicine University of Udine and Santa Maria Misericordia Hospital, Piazzale Santa Maria della Misericordia 15, 33100, Udine, Italy.

Cecilia Trucchi (C)

Health Planning unit, Azienda Ligure Sanitaria della Regione Liguria (A.Li.Sa.), Liguria Region, Italy.
Health Planning unit, Policlinic San Martino Hospital - IRCCS, Genoa, Italy.

Filippo Ansaldi (F)

Department of Health Sciences, University of Genoa, Genoa, Italy.
Health Planning unit, Azienda Ligure Sanitaria della Regione Liguria (A.Li.Sa.), Liguria Region, Italy.
Health Planning unit, Policlinic San Martino Hospital - IRCCS, Genoa, Italy.

Massimo Antonelli (M)

Department of Intensive Care and Anesthesiology, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy.

Vaclava Adamkova (V)

Clinical Microbiology and ATB Centre, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital, Prague, Czech Republic.
Department of Medical Microbiology, Medical Faculty of Palackeho University, Olomouc, Czech Republic.

Cristiano Alicino (C)

Department of Health Sciences, University of Genoa, Genoa, Italy.
Medical Direction, Santa Corona Hospital, ASL 2 Regional Health System of Liguria, Pietra Ligure, Italy.

Maria-Panagiota Almyroudi (MP)

Department of Critical Care, University Hospital Attikon, Medical School, University of Athens, Athens, Greece.

Enora Atchade (E)

Département d'Anesthésie-Réanimation, CHU Bichat-Claude Bernard, HUPNVS, APHP, Paris, France.

Anna M Azzini (AM)

Department of Diagnostics and Public Health, Infectious Disease Unit, University of Verona, Verona, Italy.

Novella Carannante (N)

First Division, Cotugno Hospital, AO dei Colli, Naples, Italy.

Alessia Carnelutti (A)

Infectious Diseases Clinic, Department of Medicine University of Udine and Santa Maria Misericordia Hospital, Piazzale Santa Maria della Misericordia 15, 33100, Udine, Italy.

Silvia Corcione (S)

Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy.

Andrea Cortegiani (A)

Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), Section of Anesthesia, Analgesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, University of Palermo, Palermo, Italy.

George Dimopoulos (G)

Department of Critical Care, University Hospital Attikon, Medical School, University of Athens, Athens, Greece.

Simon Dubler (S)

Department of Anesthesiology and Intensive Care Medicine, Heidelberg University Hospital, Heidelberg, Germany.

José L García-Garmendia (JL)

Servicio de Cuidados Críticos y Urgencias, Hospital San Juan de Dios del Aljarafe, Bormujos, Sevilla, Spain.

Massimo Girardis (M)

Department of Anesthesia and Intensive Care, University Hospital of Modena, Modena, Italy.

Oliver A Cornely (OA)

Department I of Internal Medicine, University Hospital of Cologne and Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.

Stefano Ianniruberto (S)

Infectious Diseases Unit, Department of Medical and Surgical Science, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.

Bart Jan Kullberg (BJ)

Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.

Katrien Lagrou (K)

Department of Laboratory Medicine and National Reference Centre for Mycosis, University Hospitals of Leuven, Leuven, Belgium.
Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.

Clement Le Bihan (C)

Bichat-Réanimation médicale et des maladies infectieuses, Medical ICU, Paris, France.

Roberto Luzzati (R)

Infectious Diseases Department, Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, Italy.

Manu L N G Malbrain (MLNG)

Department of Intensive Care Medicine, University Hospital Brussels (UZB), Jette, Belgium and Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

Maria Merelli (M)

Infectious Diseases Clinic, Department of Medicine University of Udine and Santa Maria Misericordia Hospital, Piazzale Santa Maria della Misericordia 15, 33100, Udine, Italy.

Ana J Marques (AJ)

C.H. Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.

Ignacio Martin-Loeches (I)

Department of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organization (MICRO), St. James's Hospital, Dublin, Ireland.
Hospital Clinic, IDIBAPS,CIBERes, universidad de Barcelona, Barcelona, Spain.

Alessio Mesini (A)

Department of Health Sciences, University of Genoa, Genoa, Italy.

José-Artur Paiva (JA)

Department of Emergency and Intensive Care Medicine, Centro Hospitalar Universitário São João, Faculdade de Medicina da Universidade do Porto e Grupo de Infecção e Sépsis, Porto, Portugal.

Maddalena Peghin (M)

Infectious Diseases Clinic, Department of Medicine University of Udine and Santa Maria Misericordia Hospital, Piazzale Santa Maria della Misericordia 15, 33100, Udine, Italy.

Santi Maurizio Raineri (SM)

Department of Biopathology and Medical Biotechnologies, Section of Anesthesia, Analgesia, Intensive Care and Emergency, Policlinico P. Giaccone, University of Palermo, Palermo, Italy.

Riina Rautemaa-Richardson (R)

Department of Infectious Diseases, Manchester University NHS Foundation Trust, Wythenshawe Hospital; and Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

Jeroen Schouten (J)

Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.

Pierluigi Brugnaro (P)

Infectious Diseases Department, Ospedale Civile SS. Giovanni e Paolo, Venice, Italy.

Herbert Spapen (H)

Intensive Care Department, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.

Polychronis Tasioudis (P)

G. Gennimatas General Hospital of Thessaloniki, Thessaloniki, Greece.

Jean-François Timsit (JF)

Université Paris Diderot/Hopital Bichat-Réanimation Medicale et Des Maladies Infectieuses, Paris, France.
UMR 1137-IAME Team 5-DeSCID: Decision SCiences in Infectious Diseases, Control and Care, Inserm/Univ Paris Diderot, Sorbonne Paris Cité, Paris, France.

Valentino Tisa (V)

Department of Health Sciences, University of Genoa, Genoa, Italy.

Mario Tumbarello (M)

Institute of Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy.

Charlotte H S B van den Berg (CHSB)

Department of Intensive Care, University Medical Center Groningen, Groningen, the Netherlands.

Benoit Veber (B)

Pole Anesthésie-Réanimation-SAMU, Rouen University Hospital, Rouen, France.

Mario Venditti (M)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Guillaume Voiriot (G)

Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Service de réanimation médico-chirurgicale, Hôpital Tenon, 75020, Paris, France.

Joost Wauters (J)

Department of General Internal Medicine, Medical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium.

Philippe Montravers (P)

Département d'Anesthésie-Réanimation, CHU Bichat-Claude Bernard, HUPNVS, APHP, Paris, France.
Université de Paris, INSERM UMR 1152, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH